Hologic, Inc. $HOLX Shares Sold by QRG Capital Management Inc.

QRG Capital Management Inc. lowered its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 52.9% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 20,777 shares of the medical equipment provider’s stock after selling 23,304 shares during the period. QRG Capital Management Inc.’s holdings in Hologic were worth $1,402,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of HOLX. Chung Wu Investment Group LLC acquired a new position in Hologic during the second quarter worth $26,000. Caitong International Asset Management Co. Ltd grew its holdings in Hologic by 193.6% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 273 shares during the last quarter. SJS Investment Consulting Inc. raised its stake in shares of Hologic by 341.5% in the third quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock worth $32,000 after acquiring an additional 362 shares during the last quarter. Loomis Sayles & Co. L P acquired a new position in shares of Hologic during the second quarter worth approximately $33,000. Finally, Cromwell Holdings LLC grew its stake in shares of Hologic by 307.0% during the second quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock valued at $38,000 after purchasing an additional 436 shares during the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Stock Up 0.2%

Shares of NASDAQ:HOLX opened at $75.11 on Wednesday. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $75.34. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.75 and a quick ratio of 3.06. The business’s 50-day moving average is $74.75 and its 200-day moving average is $70.38. The company has a market capitalization of $16.74 billion, a price-to-earnings ratio of 30.29, a P/E/G ratio of 2.13 and a beta of 0.69.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.03. Hologic had a net margin of 13.80% and a return on equity of 20.13%. The business had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.03 billion. During the same quarter last year, the firm posted $1.01 EPS. Hologic’s revenue was up 6.2% compared to the same quarter last year. Equities research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analyst Ratings Changes

HOLX has been the subject of a number of research analyst reports. Morgan Stanley upped their target price on shares of Hologic from $69.00 to $76.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 11th. Raymond James Financial cut Hologic from a “moderate buy” rating to a “hold” rating in a report on Wednesday, October 22nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hologic in a report on Friday, October 31st. BTIG Research reissued a “neutral” rating on shares of Hologic in a research report on Tuesday, October 21st. Finally, Evercore ISI downgraded shares of Hologic from an “outperform” rating to an “in-line” rating and decreased their price target for the company from $79.00 to $78.00 in a research note on Monday, January 5th. Three analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $79.29.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.